Development of peptide mimotopes of lipooligosaccharide from nontypeable Haemophilus influenzae as vaccine candidates.
Nontypeable Haemophilus influenzae (NTHi) is a common cause of otitis media in children and lower respiratory tract diseases in adults. So far there is no effective vaccine against NTHi. A major surface-exposed component of NTHi, lipooligosaccharide (LOS), is a virulence factor as well as a potential protective Ag. LOS is too toxic to be administered in humans. However, detoxified LOS is a T cell-independent small molecule and is poorly immunogenic in vivo, so we converted LOS into a nontoxic T cell-dependent Ag through the use of peptides that mimic the LOS by screening a phage-display peptide library with a rabbit Ab specific for NTHi LOS. Fifty-six phage clones were found to share LOS mimicry molecules. Among them, 22 clones were subjected to DNA sequencing, and four consensus sequences were identified as NMMRFTSQPPNN, NMMNYIMDPRTH, NMMKYISPPIFL, and NMMRFTELSTPS. Three of the four synthetic peptides showed strong binding reactivity to the rabbit anti-LOS Ab and also a mouse bactericidal monoclonal anti-LOS Ab in vitro, and elicited specific serum anti-LOS Abs in rabbits (27- to 81-fold) after conjugation with keyhole limpet hemocyanin. Passive immunization with the rabbit antisera resulted in a significantly enhanced pulmonary bacterial clearance in a mouse model. The enhanced bacterial clearance was eliminated if the rabbit serum was preabsorbed with NTHi LOS. These data indicate that the peptide mimotopes of LOS that we have identified might be potential components of peptide vaccines against NTHi.
Hou
Yingchun
Y
National Institute on Deafness and Other Communication Disorders, National Institutes of Health, Rockville, MD 20850, USA.
Gu
Xin-Xing
XX
D000818:Animals; D000907:Antibodies, Bacterial / Q000096:biosynthesis / Q000378:metabolism; D000918:Antibody Specificity; D001435:Bacteriophages / Q000276:immunology; D001666:Binding Sites, Antibody; D003001:Cloning, Molecular / Q000379:methods; D005260:Female; D006192:Haemophilus Infections / Q000276:immunology / Q000517:prevention & control; D018073:Haemophilus Vaccines / Q000138:chemical synthesis / Q000276:immunology*; D006193:Haemophilus influenzae / Q000276:immunology*; D007106:Immune Sera / Q000008:administration & dosage; D007116:Immunization, Passive; D007279:Injections, Subcutaneous; D008070:Lipopolysaccharides / Q000138:chemical synthesis / Q000276:immunology* / Q000378:metabolism; D051379:Mice; D008807:Mice, Inbred BALB C; D018716:Molecular Mimicry / Q000276:immunology*; D010446:Peptide Fragments / Q000138:chemical synthesis / Q000276:immunology*; D019151:Peptide Library; D011485:Protein Binding / Q000276:immunology; D011817:Rabbits; D018074:Vaccines, Conjugate / Q000737:chemistry / Q000276:immunology
D000907:Antibodies, Bacterial; D018073:Haemophilus Vaccines; D007106:Immune Sera; D008070:Lipopolysaccharides; D010446:Peptide Fragments; D019151:Peptide Library; D018074:Vaccines, Conjugate; C023023:lipid-linked oligosaccharides